Genmab's HuMax-CD20 cancer antibody shows promising results in primate study
Genmab A/S announced that HuMax-CD20 was effective in depleting B-cells, the target for treating non-Hodgkin's lymphoma, in both blood and lymph nodes in a pre-clinical primate study.
Furthermore, in a study up to 92 days, HuMax-CD20 depleted these B-cells for a period of time that was four times longer compared to the effect from rituximab, a marketed anti-cancer treatment against the same target. No adverse effects were observed during the study.
HuMax-CD20 is currently undergoing manufacturing development in preparation for clinical trials.